← back to search

Destin Black

Science History Institute · US
Area of research
Obstetrics and Gynecology · Reproductive Medicine
Research interest
Research interests include Endometrial and Cervical Cancer Treatments, Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, and Genetic factors in colorectal cancer.
h-index
26
citations
2,853
works
94
NIH funding
primary concept
Medicine
email

Recent publications

Recommendations for Clinical Molecular Laboratories for Detection of Homologous Recombination Deficiency in Cancer
Journal of Molecular Diagnostics 2025cited by 6position: middledoi
SURVIVAL AND SAFETY OUTCOMES IN PART 1 OF THE ENGOT-EN6-NSGO/GOG-3031/RUBY TRIAL OF DOSTARLIMAB PLUS CARBOPLATIN-PACLITAXEL IN THE PRESENCE OF COMMON COMORBIDITIES
International Journal of Gynecological Cancer 2025cited by 0position: middledoi
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
Gynecologic Oncology 2024cited by 22position: middledoi
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
New England Journal of Medicine 2023cited by 767position: middledoi
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
The Lancet 2023cited by 198position: middledoi
Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Journal of Clinical Oncology 2023cited by 3position: middledoi
The MEMORY Study: MulticentEr study of Minimally invasive surgery versus Open Radical hYsterectomy in the management of early-stage cervical cancer: Survival outcomes
Gynecologic Oncology 2022cited by 33position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Sudarshan Sharma · Sharma & Associates (United States)2 papers (2023–2025)Brian M. Slomovitz · Mount Sinai Medical Center2 papers (2023–2025)Roberto Angioli · Università Campus Bio-Medico2 papers (2023–2025)Kari L. Ring · University of Virginia2 papers (2023–2025)Lucy Gilbert · McGill University Health Centre2 papers (2023–2025) · 1 papers (2023–2023)Anna Yemelyanova · Cornell University1 papers (2025–2025)Laura Austin · Houston Methodist1 papers (2025–2025)Ian S. Hagemann · Washington University in St. Louis1 papers (2025–2025)Eric Vail · Thermo Fisher Scientific (Israel)1 papers (2025–2025)Lyndsay Willmott · Pancreatic Cancer Action Network1 papers (2025–2025)Robert L. Coleman · MD Anderson Cancer Center Madrid1 papers (2023–2023) · 1 papers (2025–2025)Bradley J. Monk · University of Cincinnati Medical Center1 papers (2023–2023)Iwona Podzielinski · University of Kentucky1 papers (2023–2023)Michael A. Gold · Nordic Society of Gynecologic Oncology1 papers (2023–2023)David M. O’Malley · Bexley Hall1 papers (2023–2023)Florian Heitz · Erasmus MC Cancer Institute1 papers (2025–2025)Dana M. Chase · UCLA Medical Center1 papers (2023–2023)Vera Paulson · Seattle Children's Hospital1 papers (2025–2025)